Subscribe to RSS
DOI: 10.1055/a-2231-5277
Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
Abstract
Case: Paroxysmal nocturnal hemoglobinuria (PNH) is an extremely rare bone marrow disorder caused by acquired mutations in the phosphatidylinositol glycan class A gene, which lead to a partial or total loss of the cellular complement regulators CD55 and CD59.[1] In addition to complement-mediated hemolysis and cytopenia, venous and arterial thromboses at multiple and/or unusual sites are a common complication and occur in up to 44% of patients in historic PNH cohorts.[1] [2]
#
A 58-year-old woman was admitted to our emergency department with a 2-day history of rapidly progressive muscle weakness of all extremities and altered behavior ([Fig. 1]). The patient reported severe headache and abdominal pain for about a week. Imaging diagnostics revealed extensive thromboses of cerebral sinus and bridging veins with congestive brain infarctions and hemorrhages ([Fig. 2A–C]). In addition, multilocular hepatic vein thrombosis ([Fig. 2E–G]) and splenic infarction were identified. In patients with multisite thrombosis, antiphospholipid syndrome, thrombotic microangiopathy, disseminated intravascular or paraneoplastic coagulopathy, antithrombin deficiency, JAK2V617F-positive myeloproliferative neoplasm, or PNH should be considered. Blood count showed mild anemia and thrombocytopenia ([Table 1]). While global coagulation tests were normal, plasma D-dimers were markedly elevated. Deficiencies in antithrombin or protein C, activated protein C resistance, dysfibrinogenemia, antiphospholipid syndrome, and JAK2V617F mutation were excluded ([Table 1]). Three days after admission ([Fig. 1]), flow cytometric analysis of peripheral blood revealed glycosylphosphatidylinositol (GPI) anchor protein deficiency in up to 65% of leukocytes and erythrocytes confirming diagnosis of PNH ([Fig. 3]). Despite immediate initiation of anticoagulation with unfractionated heparin and endovascular mechanical thrombectomy ([Fig. 2D]), the patient died few days later ([Fig. 1]). At the time of PNH diagnosis, complement inhibitory therapy was not initiated due to the patient's unfavorable clinical prognosis.
Abbreviations: aCL, anticardiolipin antibody; anti-β2GPI, anti-β2-glycoprotein-I antibody; ALT, alanine aminotransferase; APC, activated protein C; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; FVIII:C coagulation factor VIII clotting activity; INR, international normalized ratio; JAK2, Janus kinase 2; LA, lupus anticoagulant; LDH, lactate dehydrogenase; PC, protein C; PS, protein S.
Although thrombosis was fatal in our case, it can be successfully treated with therapeutic anticoagulation in combination with complement inhibitors in less severely affected PNH patients.[3] [4] Long-term complement inhibitory therapy offers the opportunity of disease control. In such patients, the risk of recurrent thrombosis is low, and thus termination of anticoagulation might even be considered.[3] [4] In addition, allogenic hematopoietic stem cell transplantation remains a curative option for some patients.[1]
In summary, although PNH is an orphan disease, it has promising treatment options. PNH should be considered in patients with newly diagnosed thromboses, especially if located at multiple and/or unusual sites.
#
Conflict of Interest
LB, TDF, FF, JF, LW, AB-H: no conflicts of interest. CB: Grants or contracts from any entity: Alexion Pharmaceuticals, Daiichi Sankyo. FL: Consulting fees: Daiichi Sankyo, Leo Pharma, Pfizer, Sanofi, Viatris; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Daiichi Sankyo, Leo Pharma, Pfizer, Sanofi, Viatris.
-
References
- 1 Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol 2023; 98 (Suppl. 04) S20-S32
- 2 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121 (25) 4985-4996 , quiz 5105
- 3 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021; 137 (10) 1304-1309
- 4 Gerber GF, DeZern AE, Chaturvedi S, Brodsky RA. A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. Am J Hematol 2022; 97 (02) E59-E62
Address for correspondence
Publication History
Received: 23 October 2023
Accepted: 18 December 2023
Article published online:
09 February 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol 2023; 98 (Suppl. 04) S20-S32
- 2 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121 (25) 4985-4996 , quiz 5105
- 3 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021; 137 (10) 1304-1309
- 4 Gerber GF, DeZern AE, Chaturvedi S, Brodsky RA. A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. Am J Hematol 2022; 97 (02) E59-E62